These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8178907)

  • 41. Estrogenic effect of gestodene- or desogestrel-containing oral contraceptives on lipoprotein metabolism.
    Gevers Leuven JA; Dersjant-Roorda MC; Helmerhorst FM; de Boer R; Neymeyer-Leloux A; Havekes L
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):358-62. PubMed ID: 2142575
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Progress in combined oral contraception: gestodene, a third generation progestogen].
    Belaïsch J
    Rev Fr Gynecol Obstet; 1989 May; 84(5):455-9. PubMed ID: 2740714
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The new pills: awaiting the next generation of oral contraceptives.
    Klitsch M
    Fam Plann Perspect; 1992; 24(5):226-8. PubMed ID: 1426186
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Norgestimate: a clinical overview of a new progestin.
    Bringer J
    Am J Obstet Gynecol; 1992 Jun; 166(6 Pt 2):1969-77. PubMed ID: 1605287
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid.
    Jespersen J; Petersen KR; Skouby SO
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):396-403. PubMed ID: 2196812
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of a monophasic and a triphasic oral contraceptive containing norgestimate.
    Corson SL
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1556-61. PubMed ID: 8178906
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
    Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
    J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative pharmacology of newer progestogens.
    Kuhl H
    Drugs; 1996 Feb; 51(2):188-215. PubMed ID: 8808163
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Clinical analysis of a new triphasic estroprogestational combination with gestodene].
    Mühe B; Vital MH
    Rev Fr Gynecol Obstet; 1988 Apr; 83(4):283-5. PubMed ID: 3393800
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins.
    Crook D; Godsland IF; Wynn V
    Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1612-20. PubMed ID: 3287933
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Effects of oral estrogen-progestin contraceptives on blood coagulation and assessment of the risk of thromboembolism].
    Surico N; Porcelli A; Petrelli P; Amedeo M; Crivello T; Ferraris G
    Minerva Ginecol; 1988 Sep; 40(9):559-62. PubMed ID: 2975773
    [No Abstract]   [Full Text] [Related]  

  • 54. Pharmacokinetics of the contraceptive steroids levonorgestrel and gestodene after single and multiple oral administration to women.
    Kuhnz W
    Am J Obstet Gynecol; 1990 Dec; 163(6 Pt 2):2120-7. PubMed ID: 2124087
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Single and multiple administration of a new triphasic oral contraceptive to women: pharmacokinetics of ethinyl estradiol and free and total testosterone levels in serum.
    Kuhnz W; Sostarek D; Gansau C; Louton T; Mahler M
    Am J Obstet Gynecol; 1991 Sep; 165(3):596-602. PubMed ID: 1892184
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The combined effect of an ethinylestradiol/desogestrel contraceptive combination on blood lipids and parameters of liver function and coagulation].
    Massafra C; Capitani S; Bernabei A; Scillone L
    Rev Fr Gynecol Obstet; 1988 Apr; 83(4):251-5. PubMed ID: 2969134
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A multicenter clinical evaluation of a new monophasic combination: Minulet (gestodene and ethinyl estradiol).
    de Andrade RP
    Int J Fertil; 1989 Sep; 34 Suppl():22-30. PubMed ID: 2576253
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 micrograms ethinylestradiol and either 150 micrograms desogestrel or 75 micrograms gestodene.
    Serfaty D; Vree ML
    Eur J Contracept Reprod Health Care; 1998 Dec; 3(4):179-89. PubMed ID: 10036600
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Inhibition of ovarian function using a triphasic combination with gestodene].
    Rozenbaum H
    Rev Fr Gynecol Obstet; 1988 Jun; 83(6):449-52. PubMed ID: 3406638
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Safety, efficacy and control of the menstrual cycle by a monophasic oral contraceptive containing 75 mcg of gestodene and 30 mcg of ethynyl estradiol].
    Alvarado Zaldivar G; Ruiz Astorga R; Arenas Arenas M; Solis Carrera L; Rueda Cisneros D; Vázquez Arreola I
    Ginecol Obstet Mex; 1993 Oct; 61():299-303. PubMed ID: 8270225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.